Immorta Bio, Inc.

First Human Administration of Senolytic Immunotherapy to Fight Cellular Aging Announced by Immorta Bio

First patient receives SenoMune™-0257, a pioneering immunotherapy designed to eliminate aging cells and advance treatment of age-related diseases…